癌研連線CancerLink
進行中（不再收案） NCT04736173

評估 Zimberelimab 與 Domvanalimab 於肺癌之療效及安全性研究

非小細胞肺癌前列腺癌膀胱癌／泌尿道上皮癌皮膚癌Phase IIIII 期IV 期PD-L1

這是一項第二期研究，評估 zimberelimab（AB122）聯合 domvanalimab（AB154）用於第一線、PD-L1 高表達、局部晚期或轉移性非小細胞肺癌（NSCLC）的療效。

適應症：Non Small Cell Lung Cancer、Nonsquamous Non Small Cell Lung Cancer、Squamous Non Small Cell Lung Cancer、Lung Cancer

收案條件

納入條件

  • Histologically confirmed, treatment naïve, locally advanced or metastatic (stage IIIB IV per AJCC version 8), squamous or non-squamous NSCLC with documented high PD L1 expression (TC ≥ 50%) as determined by the VENTANA SP263 IHC assay, as assessed by central laboratories).
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Must have at least 1 measurable lesion per RECIST v1.1
  • Adequate organ and marrow function
  • If a participant has brain or meningeal metastases, the participant must meet the following criteria:
  • Have no evidence of progression by neurologic symptoms or signs for at least 4 weeks prior to the first dose.
  • Participants with previously treated brain metastases may participate provided they have stable central nervous system (CNS) disease for at least 4 weeks prior to enrollment. Stable CNS disease is defined as resolution of all neurologic symptoms to baseline, having no evidence of new or enlarging brain metastases, and not requiring use of corticosteroids for CNS disease for at least 14 days prior to the start of study treatment. Participants who have had brain metastases resected or have received whole brain radiotherapy ending at least 4 weeks (or stereotactic radiotherapy ending at least 2 weeks) prior to initiation of study treatment are permitted.
  • Carcinomatous meningitis is excluded regardless of clinical stability.

排除條件

  • Presence of any tumor genomic aberration or driver mutation for which a targeted therapy is approved by local health authority and available
  • Use of any live vaccines against infectious diseases within 28 days of first dose
  • Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer
  • Prior treatment with any anti-PD-1, anti-PD-L1 or any other antibody targeting an immune checkpoint.

收案條件維持 ClinicalTrials.gov 原始英文登錄資料，實際收案資格以研究團隊的正式評估與受試者同意書為準。資料來源：ClinicalTrials.gov，每兩週自動更新，最後同步：2026年10月8日。